Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company’s Investigational New Drug (IND) application to expand the ongoing Phase 1 clinical program for NX-1607 into sites in the United States.
The Phase 1a/1b study, which currently includes sites in the United Kingdom, is examining the first-in-class orally dosed small molecule NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor. The multicenter, open-label Phase 1 dose escalation and expansion trial will evaluate the safety and tolerability of NX-1607 in adults with advanced malignancies which includes a variety of solid tumor indications.
Read more here